Company Profile

DIVI'S LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs
BSE5101.80-111.05 (-2.13 % )
PREV CLOSE (Rs.) 5212.85
OPEN PRICE (Rs.) 5230.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 16440
TODAY'S LOW / HIGH (Rs.)5087.65 5255.70
52 WK LOW / HIGH (Rs.)2986.7 5269
NSE5108.55 -103.55 (-1.99 % )
PREV CLOSE(Rs.) 5212.10
OPEN PRICE (Rs.) 5235.35
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 5108.55 (171 )
VOLUME 350328
TODAY'S LOW / HIGH(Rs.) 5092.00 5254.00
52 WK LOW / HIGH (Rs.)2985 5271.65

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.39
TTM EPS (Rs.) 75.88
P/E Ratio 67.23
Book Value (Rs.) 370.05
Face Value (Rs.) 2
MCap (Rs. in Mn) 1354367.60
Price/Earning (TTM) 59.24
Price/Sales (TTM) 19.24
Price/Book (MRQ) 13.79
PAT Margin (%) 28.75
ROCE (%) 31.64
Incorporation Year : 1990

Management Info :

Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director

Registered Office :

Address : 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone : 040 2378 6300

Website : www.divislabs.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
30Aug08-30-2021$Divis Laboratories informs about updates Divis Laboratories informs a
Divis Laboratories has informed that Chairman's Speech and Managing Director's Speech, delivered at the 31st Annual General Meeting of the Company held on Monday, August 30, 2021, is enclosed 

The above information is a part of company’s filings submitted to BSE.
Divis Laboratories has informed that Chairman's Speech and Mana..
09Aug08-09-2021$Divi’s Laboratories reports 13% rise in Q1 consolidated net profit Divi’s Laboratories report

Divi’s Laboratories has reported results for first quarter ended June 30, 2021.

The company has reported a rise of 12.13% in its net profit at Rs 551.97 crore for the quarter under review as compared to net profit of Rs 492.25 crore for the same quarter in the previous year. Total income of the company increased by 14.93% at Rs 1985.71 crore for Q1FY22 as compared Rs 1727.83 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 13.22% in its net profit attributed to shareholders at Rs 557.11 crore for the quarter under review as compared to Rs 492.06 crore for the same quarter in the previous year. Total income of the company increased by 14.24% at Rs 1996.61 crore for Q1FY22 as compared Rs 1747.80 crore for the corresponding quarter previous year.

Divi’s Laboratories has reported results for first quarter en..
21Jul07-21-2021$Divi’s Laboratories informs about newspaper publication Divi’s Laboratories inform

Divi’s Laboratories has informed that it has enclosed copies of notice to shareholders of the Company published in newspapers intimating that the 31st Annual General Meeting of the Company is scheduled to be held on Monday, August 30, 2021 at 10.00 am IST through video conferencing (VC) / other audio-visual means (OAVM) including other details are attached. This notice was published on July 21, 2021 in the newspapers, ‘Financial Express (English Daily) and Andhra Prabha (Telugu Daily)’.

The above information is a part of company’s filings submitted to BSE.

Divi’s Laboratories has informed that it has enclosed copies..
20Jul07-20-2021$ Announcement under Regulation 30 (LODR)-Dividend Updates Announcement under Regulati
Information regarding deduction of Income tax at source on dividend
Information regarding deduction of Income tax at source on divi..
01Jun06-01-2021$Divis Laboratories informs about annual secretarial compliance report Divis Laboratories informs a

Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular no CIR/CFD/CMD1/27/2019 dated February 08, 2019, Divis Laboratories has submitted the Annual Secretarial Compliance Report for the year ended 31 March, 2021 issued by V. Bhaskara Rao, Practicing Company Secretary, Hyderabad.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 24A of SEBI (Listing Obligations and Dis..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit5519.719547.2
Gross Profit 8137.7 26278.7
Operating Profit 8870.228832.1
Net Sales 19501.667986.1
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
JB Chem & Pharma (BSE)
 1836.10 (5.26%)
M.Cap ( in Cr)
14189.77
Alkem Laboratories (BSE)
 4001.85 (0.95%)
M.Cap ( in Cr)
47848.12
Kwality Pharma (BSE)
 688.70 (4.99%)
M.Cap ( in Cr)
714.61
Hester Biosciences (BSE)
 2518.75 (0.91%)
M.Cap ( in Cr)
2142.67
Procter&Gamble Healt (BSE)
 5381.55 (0.34%)
M.Cap ( in Cr)
8933.04
Shareholding Pattern More
PROMOTERS 51.95 %
MUTUAL FUNDS/UTI 12.61 %
NON-INSTITUTION 10.89 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes